Valtoco Nasal Product
Phase 3Small molecule
Valtoco Nasal Product is one of 49 small molecule programs targeting Epilepsy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Fycompa
CCatalyst Biosciences
Approved
Diamox
TevaApproved
Briviact
UCBPhase 3
Zoloft
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Coreg
Akero TherapeuticsApproved
Glucophage
EMD SeronoApproved
Advil
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Epilepsy1 trial
Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care
Active, not recruiting·UUniversity Hospitals Cleveland Medical Center·Approved·NCT06346262·31 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Valtoco Nasal Product. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details